IPM.ai, Part of Real Chemistry, Named by Fast Company as One of the World's Most Innovative Companies For 2022

Recognition underscores IPM.ai's AI-powered approach to finding undiagnosed and misdiagnosed patients suffering from specialty and rare diseases

SAN FRANCISCO--(BUSINESS WIRE)--IPM.ai, part of Real Chemistry and a leader in uncovering undiagnosed and misdiagnosed patients for specialty and rare disease via machine learning and artificial intelligence, today announced it has been named by Fast Company as one of the World's Most Innovative Companies for 2022.

IPM.ai was named #2 in the Data Science category in recognition of its transformational approach to inform and accelerate the development, clinical study and commercialization of precision medicine by health care and life sciences companies. Each year, Fast Company editors and reporters work to identify and recognize organizations transforming industries, shaping society, and moving the world forward. Since its inception in 2008, its World’s Most Innovative Companies list has been the definitive source for identifying innovative companies moving the world forward.

"We are honored and privileged to be named as one of the world’s Most Innovative Companies in Data Science by Fast Company," said IPM.ai co-founder and president Ron Elwell. "Rare diseases pose distinct challenges for drug development, particularly at critical decision points in the product lifecycle. With small and largely undiagnosed populations, traditional approaches to patient finding for these conditions are reliant on previously diagnosed patients and typically result in highly inaccurate outcomes. Our approach uncovers patients with the highest likelihood of disease manifestation, whether diagnosed, undiagnosed or misdiagnosed, leading to earlier disease interception and optimal patient outcomes faster and with less risk.”

IPM.ai's HIPAA-compliant system of insight applies artificial intelligence and machine learning against a tokenized, real world data universe of more than 300 million de-identified patient journeys, 65 billion anonymous social determinants of health signals and first-party sources of any type and scale such as genetic testing, laboratory research and epidemiological asessments. By uncovering patients who present with a rare disease using privacy-safe real world data, IPM.ai creates the ideal patient definition, models undiagnosed and misdiagnosed lookalike patients and maps patient treatment journeys to associated primary care physicians and specialists. This augmented intelligence approach can be applied across the product lifecycle, from rapidly assessing the size of a market for an orphan drug to uncovering patients with the highest propensity for successful clinical study screening and those most likely to begin a newly launched or in-market therapy.

“Patients with rare diseases face seemingly insurmountable odds,” added Real Chemistry CEO Shankar Naryanan. “They are undiagnosed or misdiagnosed for six years on average, and consult more than seven physicians during their diagnostic and treatment odyssey, resulting in low quality of life, extreme burden on caregivers and financial hardship. By uncovering these patients and their associated health care providers, IPM.ai helps connect the precision medicine pioneers with novel treatments to those most in need earlier, transforming the lives of patients and their loved ones.”

About IPM.ai and Real Chemistry

IPM.ai, part of Real Chemistry (www.ipm.ai), transforms real-world data into real-world insights that uncover the ideal patient and their healthcare ecosystem so that life sciences companies can accelerate the successful development, clinical study and commercialization of critical therapies for specialty and rare diseases. IPM.ai’s Insights as a Service (IaaS) platform optimizes drug development, clinical study, product launch and commercial operations by utilizing granular-level longitudinal analytics, artificial intelligence and machine learning in conjunction with a real-world data universe of over 300 million de-identified patient journeys and 65 billion anonymized social determinants of health signals. We’re making the promise of precision medicine an analytical reality. And we are just getting started.

Real Chemistry is making the world a healthier place by empowering patients to access the right treatment at the right time. We leverage the best data-driven, tech-enabled and digital solutions to deliver communications, engagement, activation and value across a full range of diverse health care stakeholders — patients, payors, providers, caregivers and regulators.

For more information, please visit at www.pm.ai and connect with us on LinkedIn or Twitter